NASDAQ:RNAZ - Nasdaq - US89357L4023 - Common Stock - Currency: USD
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
/PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating...
U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Futures of benchmark indices were lower in premarket.
/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating...
TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session.
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.
/PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating...
TransCode Therapeutics (RNAZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
/PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating...
/PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...